Evidence based radiation therapy for locally advanced resectable and unresectable gastric cancer

Table 1 Randomized trials for postoperative chemo-radiotherapy in resectable gastric cancer

Author, year published	Nr Pt	Treatment arms	Local control	Overall survival
Moertel et al[12], 1984	62	Arm 1 (23 patients): Observation only Arm 2 (39 patients): 5-FU (15 mg/kg by rapid intravenous injection × 3) plus radiation (3750 rad in 24 fractions)	The alive without recurrence distributions were significantly different for the two groups (P = 0.024) and favored treatment assignment.	The five year survival rate for patients randomized to treatment was 23%, and for those randomized to no treatment, 4% (P < 0.05).
Kim et al[15], 2005	990	Arm 1 (446 patients): no adjuvant treatment Arm 2 (544 patients): 400 mg/m2 of 5-FU plus 20 mg/m2 of LV for 5 d, followed by 4500 cGy of RT for 5 wk, with 5-FU and LV on the first 4 and the last 3 d of RT. Two additional cycles of the chemotherapy were given 4 wk after the completion of RT	The CRT was associated with increases in the median duration of relapse-free survival (75.6 mo vs 52.7 mo; hazard ratio for relapse, 0.80, P = 0.016).	Overall survival was significantly longer in the CRT arm: 95.3 mo vs 62.6 mo (hazard ratio for death of 0.80, P = 0.02)

Nr: Number; Pt: Patients; 5-FU: 5-fluorouracil; LV: Leucovorin; CRT: Chemo-radiotherapy.